Negative Shocks May Hit Twice in Pharmaceutical Development
One defining aspect of the pharmaceutical industry is its high exposure to negative shocks—product recalls, tornados that shut down production lines, Phase III failures, you name it. As my thinking about some of these shocks has grown over time, I’ve come to realize some shocks may hit twice—the second time being the moment a sub-par decision is made in an attempt to recover from the original hit. With stakes being so high, it seems particularly important for leaders in this industry to remain aware that they are not immune to the perils of reactive decision making.